Keyword: Amylin

News

Eli Lilly Broadens Diabetes Offer

03.05.2013 - Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market. The global...

News

Eli Lilly Banks on Cost Controls for Higher 2013 Profit

04.01.2013 - Eli Lilly said on Friday it expects profit in 2013 to increase by more than Wall Street had been forecasting, primarily due to cost controls and improved productivity. Lilly, whose...

News

The European Pharmaceuticals Economy at Halftime 2012

25.09.2012 - A Pill a Day - Unlike chemicals, the pharmaceuticals sector does not have cycles. Even in a sluggish economy, sick people will still need medicine. But the widening European debt...

News

AstraZeneca Buys Equal Say over Amylin Drugs

10.08.2012 - AstraZeneca has opted to pay a further $135 million to Bristol-Myers Squibb to get an equal say in decision-making regarding drugs developed by Amylin Pharmaceuticals, the diabetes...

News

Biotech M&A at 4-Year High as Pharma Faces Expiring Patents

03.08.2012 - Global biotech merger volume has reached levels not seen in four years as big pharmaceutical companies pursue deals to get access to new drugs, with bankers saying therapeutic...

News

Bristol-Myers Executive Charged with Insider Trading

02.08.2012 - A Bristol-Myers Squibb executive has been criminally charged with insider trading, accused of buying options in three companies that the drugmaker was looking to buy. Prosecutors...

News

Surge in Biotech Deals to Unlock Big Investor Profits

18.07.2012 - Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors' average cost...

News

AstraZeneca Hungry to Refill Medicine Cabinet

30.06.2012 - Simon Lowth may only be the interim chief executive of AstraZeneca but he is ready to sign off on bold deals. The decision to pair up with Bristol-Myers Squibb to buy diabetes...